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Abstract 
 
During the 10th International Symposium on Sjögren’s Syndrome held in Brest, 
France, from October 1-3, 2009 (http://www.sjogrensymposium-brest2009.org), the 
creation of an international epigenetic autoimmune group has been proposed to 
establish gold standards and to launch collaborative studies. During this “epigenetics 
session”, leading experts in the field presented and discussed the most recent 
developments of this topic in Sjögren’s Syndrome research. The “Brest epigenetic 
task force” was born and has scheduled a meeting in Ljubljana, Slovenia during the 
7th Autoimmunity congress in May 2010.The following is a report of that session. 
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Take-home messages: 
 
 Epigenetic regulatory mechanisms comprise DNA methylation, a variety of 
histone modifications, and microRNA activity; all of which act upon gene and 
protein expression levels. 
 Increased activity and destructive potential of synovial fibroblasts in 
rheumatoid arthritis is due in part to the deregulation of epigenetic factors. 
 Development of an epigenetic bank and the establishment of gold standards in 
an epigenetic consortium to analyse epigenetic modifications are needed. 
 Epigenetic alterations in autoimmune diseases could be used as 
prognostic/diagnostic tools and markers of immune cell activation. 
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1. Introduction 
 
The mechanisms causing most human autoimmune diseases remain obscure. Although 
genes and genetic loci causing predispositions to autoimmunity are being identified, 
incomplete disease concordance in identical twins indicates that non-genetic factors 
and mechanisms also contribute to autoimmune etiologies. Eukaryotic gene 
expression requires not only the regulated activity of transcription factors, but also a 
transcriptionally permissive regional chromatin configuration. The structure of 
chromatin is regulated by epigenetic mechanisms, primarily DNA methylation and 
histone modifications. Several recent studies have demonstrated that disrupting the 
epigenetic regulation of transcription plays crucial roles in the development of 
autoimmune diseases. The main purpose of the “epigenetics session” at Brest was not 
only to present recent academic works, but also to obtain a more comprehensive view 
of the current state of epigenetics research in the international autoimmunity 
community. 
Epigenetic modifications are changes in gene expression that can be maintained 
throughout a cell’s life and be passed on through cell division, and thus can remain 
persist in the organism without alterations in DNA sequences. Epigenetic factors are 
associated with a great number of diseases, including cancer, autoimmune disorders, 
heart diseases and skin diseases. Since drugs that can reverse aberrant gene expression 
profiles are readily available, the identification and subsequent modification of 
epigenetic markers involved in disease development may provide important novel 
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therapeutic approaches for autoimmune disorders.  
 
2. What are epigenetic modifications? 
 
Epigenetic regulatory mechanisms comprise DNA methylation, a variety of histone 
modifications, of which the best characterized is acetylation, and microRNA activity; 
all of which act upon gene and protein expression levels [1-3]. In vertebrates, DNA 
methylation is defined as the postsynthetic addition of methyl groups to cytosine 
bases, generally only those in CpG pairs, at position 5 of the pyrimidine ring, and 
catalyzed by a DNA methyltransferase (DNMT). About 70% of CpG dinucleotides in 
human DNA are methylated in pairs, while most of the unmethylated CpGs are 
situated in CpG islands. CpG islands are CG-rich sequences located near coding 
sequences, and often contain regulatory elements for nearby genes. Approximately 
half of mammalian gene loci have CpG islands [1]. DNA methylation leads to gene 
silencing by binding methyl-CpG-binding proteins, such as MeCP2 and MBD2, 
which then recruit chromatin inactivation complexes containing histone deacetylases 
(HDACs) and histone methyltransferases (HMTs). Chromatin inactivation complexes 
promote the condensation of DNA into a transcriptionally restrictive configuration in 
the regions encompassing methylated sequences. DNA methylation may also interfere 
with the binding of some transcription factors [2]. 
Histone modifications regulate gene expression by changing the degree to which gene 
loci are accessible to transcription machinery. The N-terminal tail of histones protrude 
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from nucleosomal core particles and are subject to an array of post-translational 
modifications[3]. These modifications include, but are not limited to, acetylation, 
methylation, phosphorylation, ADP-ribosylation, sumoylation and ubiquitination. 
MicroRNAs (miRNAs) are a group of post-transcriptional regulators involved in 
many biological processes including development, differentiation, proliferation and 
apoptosis [4]. miRNAs are ~22nt-long non-coding RNAs that suppress translation by 
binding to, and thereby causing the degradation of, complementary target mRNA 
species [5]. Briefly, miRNAs are genome-encoded and transcribed by RNA 
polymerase II, similar to ordinary protein-coding RNAs. Transcription of a 
miRNA-coding gene generates a primary transcript, known as pri-miRNA, that 
contains a polyA tail and 7-methylguanosine cap. The pri-miRNA is processed into a 
70-nt stem-loop structure called pre-miRNA by the RNase III enzyme Drosha. 
Exportin 5 imports the pre-miRNA to the cytoplasm where it is further processed by the 
RNase III protein Dicer into an unstable 19-25 nt miRNA duplex structure that 
possesses a ‘guide strand’ (miR) and a ‘passenger strand’ (miR*). miR* is degraded 
and miR becomes the mature miRNA that is incorporated into the RNA-induced 
silencing complex (RISC) to regulate protein expression [4]. 
 
3. Epigenetic modifications and autoimmune diseases 
 
Continued efforts in the field of epigenetics have led to the discovery of associations 
between every epigenetic modification mentioned above and one or more 
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autoimmune disorder. Specific epigenetic defects associated with rheumatoid arthritis 
(RA), systemic lupus erythematosus (SLE), primary Sjögren’s syndrome (pSS) and 
systemic sclerosis (SSc) were presented and are summarized below. 
 
3.1. rheumatoid arthritis 
 
RA is an autoimmune disease characterized by chronic joint inflammation that can 
cause progressive and irreversible destruction of articular cartilage. Although the 
cause of RA is unknown, a combination of genetic susceptibility factors, deregulated 
immunomodulation and environmental influences is generally considered to be at the 
root of autoimmune responses that occur in synovial joints of RA patients. 
In recent years, Steffen Gay (University Hospital Zürich, Switzerland) and his 
colleagues have pursued the idea that, along with immune cells, synovial fibroblasts 
residing in the joint space play important roles in the perpetuation, and perhaps even 
the initiation of RA. Moreover, they have found that the increased activity and 
destructive potential of RA synovial fibroblasts (RASFs) is due in part to the 
deregulation of epigenetic factors.  
As discussed by Dr. Gay, synovial tissue DNA in RA patients is hypomethylated, and 
when normal synovial fibroblasts are treated with the DNMT inhibitor 5-AZA 
(5-aza-2′-deoxycytidine), they develop a RASF-like phenotype [6, 7]. A recently 
published report also provides evidence of histone hyperacetylation in synovial tissue 
samples from animals with a RA-like condition compared to animals with 
 6
osteoarthritis (OA). Furthermore, the authors find the activity of HDACs to be about 
two-fold lower in synovial extracts from RA patients compared to OA patients [8]. 
Lastly, a recent study has suggested that the expression and function of specific 
miRNAs, possibly miR-155 and miR-146, might also be involved into the 
pathogenesis of RA [9]. 
With regards to the involvement of miRNAs in autoimmune disorders, the 
discussion focused mainly on the role of miRNA-expressing microparticles and their 
utility as prognostic/diagnostic tools and markers of immune cell activation, or their 
potential role on target cells. 
 
 
3.2. Systemic lupus erythematosus 
 
SLE is an autoimmune disorder characterized by the overproduction of 
auto-antibodies, which ultimately lead to autoimmune responses and tissue damage in 
multiple organs. Both genetic and environmental factors contribute to the 
development of the disease, but the specific interplay between immune system and 
environmental factors that leads to disease in genetically predisposed hosts remains 
poorly understood. 
Several studies from Dr. Lu’s group (Epigenetic Research Center, Central South 
University, China) and others have uncovered the importance of DNA 
hypomethylation in the etiology of SLE [10, 11]. Specifically, recent evidence 
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suggests that modulations in DNA methylation due to environmental agents may 
affect the structure of T cell chromatin, disrupting gene expression and resulting in 
immune system hyperactivity. The changes in DNA methylation are regulated by the 
extracellular signal-regulated kinase (ERK) signaling pathway [12], and transgenic 
mice expressing dominant-negative MEK in T cells display lupus-like T cell 
auto-activation. Decreased ERK pathway signaling in the T cells of these mice leads 
to decreased expression of DNMT1 and overexpression of methylation-sensitive 
autoimmunity genes, such as CD11a and CD70, similar to T cells in human lupus [13]. 
Demethylating drugs such as 5-azacytidine (5-aza), procainamide and hydralazine can 
also induce lupus-like autoimmunity, both in vitro and in vivo [11]. 
In general, histone modifications appear abnormal in SLE. However, compared with 
healthy controls, global acetylation of histones H3 and H4 in active lupus CD4+ T 
cells is decreased and H3 acetylation levels negatively correlate with disease activity 
in lupus patients (as measured by SLEDAI). Global H3K9 hypomethylation is also 
observed in both active and inactive lupus CD4+ T cells compared with controls, 
whereas H3K4 methylation levels do not differ between patients and controls [14]. 
The splenocytes of MRL-lpr/lpr mice (which have a lupus-like condition) also exhibit 
histones H3 and H4 hypoacetylation, although there is an overall global site-specific 
hypermethylation in these mice compared to controls. These mice also exhibit histone 
modification defects that have not yet been identified in patients, such as H3K18 
methylation, H4K31 methylation, and H4K31 acetylation [15]. 
Another recent study showed that miR-146a, a negative regulator of the interferon 
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(IFN) pathway, contributes to the pathogenesis of SLE. By targeting the key signaling 
components, decreased levels of miR-146a lead to increased type I IFN pathway 
activity in lupus patients [16]. In addition, Dai et al [17] identified 16 miRNAs that 
are differentially expressed in SLE. 
 
3.3. Primary Sjögren’s syndrome 
 
At the “epigenetics session”, Gabor Illei (NIH, Bethesda, USA) presented his results 
showing that two miRNAs (miR-574 and miR-768-3p) are overexpressed in the 
salivary glands of SS patients. He reported that these two suspected epithelial cell 
miRNAs could be used to predict the evolution of the disease. Seunghee Cha 
(University of Florida, USA) presented data obtained from her studies of non-obese 
diabetic (NOD) mice (B6DC) that develop a disease similar to human SS [18]. She 
highlighted two miRNAs (150 and 146) that are upregulated in target tissues and in 
PBMCs of B6DC mice compared to control mice. Dr. Cha also reported that miR-146 
expression is increased in PBMCs and salivary glands of SS patients.  
 
3.4. Systemic sclerosis  
 
Defective T-cell DNA methylation is also associated with SSc, an autoimmune 
disorder characterized by vasculopathy and widespread organ fibrosis. CD4+ T-cell 
DNA from patients with SSc is significantly hypomethylated relative to healthy 
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controls, and the levels of DNMT1, MBD3, and MBD4 mRNAs are significantly 
decreased in SSc patients [19]. Furthermore, reduced expression of DNMT3a results 
in enhanced histone acetylation. Fibroblasts synthesize exuberant levels of collagen in 
SSc and this phenotype is linked to hypermethylation-dependent repression of the 
collagen suppressor gene FLI1. CpG islands in the FLI1 promoter region are heavily 
methylated in SSc fibroblasts, as well as in skin biopsy specimens [20]. During the 
10th SS Symposium, Carlo Selmi (University of Milan, Italy) presented his work 
regarding the importance of X chromosome deletion (monosomy X) in Primary 
biliary cirrhosis (PBC) and scleroderma [21] Dr. Selmi opened a discussion on the 
importance of conducting a twin studies to uncover the role of epigenetic 
modifications that affect the expression of X chromosome encoded 
autoimmune-related genes. 
 
4. Epigenetic consequences 
 
4.1. B and T cell autoreactivity 
 
Yves Renaudineau (University of Brest, France) presented evidence detailing the 
contribution of DNA demethylation defects to the autoreactivity of B cells [22]. 
Indeed, testing the influence of IL-6 overproduction by SLE B cells, it was observed 
that IL-6 abrogates the ability of SLE B cells to induce DNMT1, and then to 
methylate DNA. This effect is reversed in the presence of a blocking monoclonal 
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antibody to IL-6 receptor, and reproduced in B cells from healthy controls when the 
cells are stimulated in the presence of IL-6, or treated with a DNMT1 inhibitor. Such 
effect has been attributed to an IL-6-dependent cell cycle blockage in B cells allowing 
overexpression of genes such as human endogenous retrovirus (HERV) and the BCR 
rearrangement X [23, 24].Animal models support also that DNA methylation is 
associated with activation of lymphocytes, leading to the development of an SLE-like 
disease with autoantibody production. This was demonstrated using DNMTs 
inhibitors orally administrated or after adoptive transfer using pre-treated CD4+ T 
cells or bone marrow B cells [25]. 
 
4.2. Epigenetic protein modifications and autoantibody recognition 
 
Athanasios Tzioufas (University of Athens, Greece) and Stefano Bombardieri 
(University of Pisa, Italy) reported that histones and other nucleic acid binding 
proteins can be subject to epigenetic post-translational modifications (acetylation, 
methylation, phosphorylation, ADP-ribosylation, sumoylation and ubiquitination) [26, 
27]. These proteins include autoimmunity-related genes such as Ro60 and Sm, and 
specific recognition by auto-antibodies may underlie epigenetic modifications in 
autoimmune diseases. As a consequence it has been proposed that these 
autoantibodies should be important as tool for diagnosis or as prognostic biomarker. 
 
4.3. New epigenetic therapeutics 
 11
 Finally, Wesley Brooks (Drug Discovery, Tampa, USA) reported that blocking the 
human S-Adenosylmethionine (SAM) Decarboxylase with a specific inhibitor 
prevents the SAM's degradation [28]. As a consequence this new drug should reduce 
the DNA methylation observed in autoimmune diseases by providing more SAM to 
the cell. The mechanisms leading to SAM-decarboxylase overexpression in 
autoimmune diseases were also presented and may be related to the over-expression 
of the putrecine's pathway (by virus and or as a consequence of the Chromosome X 
demethylation) [29] 
 
4.4. Establishment of seven epigenetic working groups 
 
At the conclusion of the “epigenetics session”, the participants proposed the creation 
of an international epigenetic autoimmune group, which would establish gold 
standards and promote cooperation within the research community. 
Seven tentative working groups were formed. These groups aim to pursue the 
following: 
1. Validating and optimizing miRNA markers for autoimmune diseases. 
2. Defining HERV markers for autoimmunity. 
3. Investigating the role of DNA methylation and related enzymes in autoimmune 
diseases. 
4. Investigating post-translational modifications and auto-antibody recognition. A 3D 
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bio-computer scientist will likely be required for this group. 
5. Investigating the role of X chromosome genes in autoimmunity. 
6. Twin studies. 
7. Drug discovery related to epigenetic autoimmunity factors. 
 
5. Concluding remarks 
 
The “epigenetics session” of the 10th International Symposium on SS provided an 
opportunity to relate and discuss the latest research findings in the field of epigenetics. 
Participants candidly agreed on the creation of a worldwide epigenetic bank and to the 
development of gold standards in an epigenetic consortium. The momentum in the 
field is considerable, and all participants look forward to the “epigenetics session” 
that will take place during the Autoimmunity Congress in Ljubljana, May 5-9, 2010. 
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